Lumenis reports exciting study outcomes for its endometriosis treatment

Lumenis announced the publication of meaningful new clinical evidence for its surgical intervention for patients with endometriosis. The study was published in the the Journal of Endometriosis and Pelvic Pain Disorders (JEPPD).

The aim of the study was to evaluate the benefits of CO2 laser vaporization through a clinical trial assessing the postoperative changes in ovarian reserve as indicated by antral follicle count (AFC) and anti-Müllerian hormone (AMH). Antral Follicle Count test is a study that measures a woman's ovarian reserve, or her remaining egg supply. The ovarian reserve reflects her fertility potential. AMH is expressed by granulosa cells of the ovary during the reproductive years. Some authorities suggest it is a measure of certain aspects of ovarian function.

The AFC of the operated ovary was significantly increased after treatment at 1 and 3 months’ follow-up (p = 0.0021; p = 0.005, respectively); the increase is particularly significant in women younger than 35 years (p = 0.012). No statistically significant changes were reported in serum AMH concentrations at 1 or 3 months’ follow-up. No recurrences of symptoms and no recurrences of endometrioma were reported.

The researchers concluded that the data support the hypothesis that endometrioma vaporization with CO2 laser fiber may be a valid method to preserve ovarian function. Also noting, however, further studies are required before advocating the routine use of CO2 laser vaporization for the management of ovarian endometriosis.

Holly Sanneman, founder and director of the nonprofit American End of Endo Project, has undergone endometriosis surgery with the Lumenis CO2 laser and is now an advocate of the technology. She tells other women with endometriosis, "I would emphatically recommend this procedure to other people, for everybody who is searching or has lost hope. You can get your life back!"